Vor Biopharma Inc

NASDAQ VOR

Data sourced from

and

Daily

Download Data

Vor Biopharma Inc Price to Book Ratio (P/B) on June 03, 2024: 0.79

Vor Biopharma Inc Price to Book Ratio (P/B) is 0.79 on June 03, 2024, a -44.65% change year over year. The price to book ratio compares the market price per share of a company's stock to its book value per share. It is calculated by dividing the market capitalization by the shareholders' equity minus treasury stock, divided by the number of outstanding shares. This ratio provides insights into how the market values a company relative to its book value. A ratio above 1 indicates the market values the company more than its book value, suggesting positive market sentiment.

Vor Biopharma Inc 52-week high Price to Book Ratio (P/B) is 862.30 on August 08, 2023, which is 108,589.39% above the current Price to Book Ratio (P/B).
Vor Biopharma Inc 52-week low Price to Book Ratio (P/B) is 0.00 on March 14, 2024, which is -99.89% below the current Price to Book Ratio (P/B).
Vor Biopharma Inc average Price to Book Ratio (P/B) for the last 52 weeks is 11.16.

NASDAQ: VOR

Vor Biopharma Inc

CEO	Dr. Robert Ang M.B.A., M.D., MBBS
IPO Date	Feb. 5, 2021
Location	United States
Headquarters	100 Cambridgepark Drive, Cambridge, MA, United States, 02140
Employees	168
Sector	Healthcare
Industry	Biotechnology

Description

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Key trends